Via Kristy Dorsey
In an attempt to minimise waiting lists for activities that have swelled in the aftermath of the coronavirus pandemic, a Scottish start-up will test the technology at one of the country’s largest healthcare organisations.
The trial follows Infix’s initial funding of £ 300,000, which was developed by NHS consultant anaesthetist Matthew Freer in September 2019. A £ 130,000 grant from Innovate UK and £ 170,000 from a number of private investors is included in the funding.
A patient database tool designed to reduce waiting list backlogs and maximise the usage of operating rooms has been developed by Infix. It also helps cancer and other urgent patients to be prioritised by doctors to maximise overall results.
Green light for Omega Diagnostics in China
“The trial with NHS Lanarkshire will allow us to demonstrate the efficacy of Infix before rolling it out to other health boards in Scotland,” Dr. Freer said.
“The progress we’re making on the product roadmap has also led to discussions with NHS health boards in England and other health organisations outside the U.K.”
Fintech of Edinburgh acquires Glasgow business
Infix has added two new members to its board after the investment round closed with Innovate UK funding in September. They are the founder and CEO of Tracedata, Sorcha Lorimer, and the founder and CEO of Forrit, Peter Proud.
Infix said it now plans in the first half of next year to “step up” its partnership with angel and venture capital companies.